Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature
Background Little data are available about the safety of TNF‐α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature.
S Piaserico, P Dapavo, A Conti, P Gisondi, FP Russo - 2017 - cabidigitallibrary.org
Background: Little data are available about the safety of TNF-α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
[引用][C] Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the …
S Piaserico - Journal of the European Academy of …, 2017 - Wiley Online Library
We thank Ricceri et al. for their comments (1) and interest in our study (2). Despite the recent
advances in prevention and treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) …
advances in prevention and treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) …
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature.
S Piaserico, P Dapavo, A Conti, P Gisondi… - Journal of the …, 2017 - europepmc.org
Background Little data are available about the safety of TNF-α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature.
S Piaserico, P Dapavo, A Conti, P Gisondi… - JOURNAL OF THE …, 2017 - research.unipd.it
BACKGROUND: Little data is available about the safety of TNF-α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature
S Piaserico, P Dapavo, A Conti… - Journal of the …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Little data are available about the safety of TNF-α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature
S Piaserico, P Dapavo, A Conti, P Gisondi… - JOURNAL OF THE …, 2017 - iris.univr.it
Background Little data are available about the safety of TNF-alpha inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …
[引用][C] Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the …
S Piaserico - JOURNAL OF THE EUROPEAN ACADEMY OF …, 2017 - research.unipd.it
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a
multicentre cohort study of 37 patients and review of the literature. Reply to Dr. Ricceri letter …
multicentre cohort study of 37 patients and review of the literature. Reply to Dr. Ricceri letter …
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature …
S Piaserico - Journal of the European Academy of Dermatology and …, 2017 - europepmc.org
This is a comment on" Adalimumab is a safe option for psoriasis patients with concomitant
hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the …
hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the …
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature …
S Piaserico - Journal of the European Academy of …, 2017 - pubmed.ncbi.nlm.nih.gov